冠動脈動脈硬化症の進化に有益な影響を与える介入. カルシウムチャネルブロッカーのケース
1Department of Medicine, Montreal Heart Institute, Quebec, Canada.
Circulation
|December 1, 1992
まとめ
カルシウムチャネルブロッカーは,冠動脈動脈硬化症の管理に潜在力を示しています. 臨床試験は,これらの薬が最小限の病変の進行を遅らせ,新しい冠動脈病変の形成を減らす可能性があることを示しています.
科学分野:
- 心血管医学 心血管医学
- 薬理学 薬理学とは
背景:
- カルシウムチャネルブロッカー (CCB) は,様々なメカニズムを通じて動脈硬化症の進行を阻害する可能性があります.
- 潜在的なメカニズムには,コレステリルエステルヒドローラゼを刺激し,内皮機能を改善したり,滑らかな筋肉細胞の増殖を抑制したりすることが含まれます.
研究 の 目的:
- 人における冠動脈動脈硬化症の進行に対するCCBの効果を評価する.
- ニカルディピンとニフェディピンが冠動脈病変の進化に与える影響を評価する.
主な方法:
- 2つの臨床試験が実施されました:モントリオール心臓研究所試験と抗動脈硬化療法に関する国際ニフェディピン試験です.
- これらの試験では,患者の冠動脈動脈硬化症の進行と逆行を評価した.
主要な成果:
- ニカルディピンは,全般的な動脈硬化症の進行に影響を及ぼさなかったが,最小限の病変 (<または=20%の狭窄症) の進行を減少させた.
- ニフェディピンは,全体的な進行または回帰に効果を示さなかったが,新しい冠動脈病変の形成を減少させた.
結論:
- CCBは,冠動脈動脈硬化症の管理のための有望な治療戦略を表しています.
- 特定のCCBは,動脈硬化病変の発生のさまざまな側面に影響を与える可能性があります.
関連する概念動画
Antihypertensive Drugs: Action of Calcium Channel Blockers
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...


